DD244357A5 - Verfahren zur Herstellung einer oralen Vakzine - Google Patents
Verfahren zur Herstellung einer oralen Vakzine Download PDFInfo
- Publication number
- DD244357A5 DD244357A5 DD28223185A DD28223185A DD244357A5 DD 244357 A5 DD244357 A5 DD 244357A5 DD 28223185 A DD28223185 A DD 28223185A DD 28223185 A DD28223185 A DD 28223185A DD 244357 A5 DD244357 A5 DD 244357A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- adenovirus
- virus
- item
- gene
- hepatitis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 229940126578 oral vaccine Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 4
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 63
- 241000700605 Viruses Species 0.000 claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 208000015181 infectious disease Diseases 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 230000002458 infectious effect Effects 0.000 claims abstract description 20
- 230000007969 cellular immunity Effects 0.000 claims abstract description 11
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 241000702670 Rotavirus Species 0.000 claims description 9
- 241000701096 Human adenovirus 7 Species 0.000 claims description 6
- 241001135572 Human adenovirus E4 Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 claims description 2
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims description 2
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 206010040550 Shigella infections Diseases 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 208000001786 gonorrhea Diseases 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 201000005113 shigellosis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 21
- 229960005486 vaccine Drugs 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 239000013598 vector Substances 0.000 description 14
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- 108700012261 Rotavirus VP7 Proteins 0.000 description 8
- 230000008488 polyadenylation Effects 0.000 description 8
- 241001135569 Human adenovirus 5 Species 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 108020005202 Viral DNA Proteins 0.000 description 4
- 229940021704 adenovirus vaccine Drugs 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 101100190323 Caenorhabditis elegans phm-2 gene Proteins 0.000 description 3
- 241000701109 Human adenovirus 2 Species 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical group O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001446459 Heia Species 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 1
- 101001047819 Homo sapiens Heparanase Proteins 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108700010850 rotavirus proteins Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66723384A | 1984-11-01 | 1984-11-01 | |
US78263885A | 1985-10-04 | 1985-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DD244357A5 true DD244357A5 (de) | 1987-04-01 |
Family
ID=27099642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD28223185A DD244357A5 (de) | 1984-11-01 | 1985-10-30 | Verfahren zur Herstellung einer oralen Vakzine |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP0181117B1 (ja) |
JP (2) | JP2609447B2 (ja) |
KR (1) | KR930012116B1 (ja) |
AT (1) | ATE82509T1 (ja) |
AU (1) | AU576907B2 (ja) |
CA (1) | CA1263305A (ja) |
DD (1) | DD244357A5 (ja) |
DE (1) | DE3586841T2 (ja) |
DK (1) | DK501785A (ja) |
ES (1) | ES8900007A1 (ja) |
FI (1) | FI854257L (ja) |
GB (1) | GB2166349B (ja) |
GR (1) | GR852592B (ja) |
HK (1) | HK5692A (ja) |
HU (1) | HU195619B (ja) |
IE (1) | IE58205B1 (ja) |
IL (1) | IL76751A (ja) |
MX (1) | MX9203610A (ja) |
MY (1) | MY101343A (ja) |
NO (1) | NO854347L (ja) |
NZ (1) | NZ213920A (ja) |
PL (1) | PL256049A1 (ja) |
PT (1) | PT81367B (ja) |
SG (1) | SG85391G (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0251467A3 (en) * | 1986-06-20 | 1988-07-20 | Abbott Laboratories | Compositions and methods of use for a major outer capsid protein (vp7) of rotavirus sa-11 |
NZ220645A (en) * | 1986-06-20 | 1989-10-27 | Merck & Co Inc | Modified varicella-zoster virus and its cultivation |
EP0275300B1 (en) * | 1986-08-01 | 1996-01-03 | Commonwealth Scientific And Industrial Research Organisation | Recombinant vaccine |
US5866136A (en) * | 1986-08-01 | 1999-02-02 | Commonwealth Scientific And Industrial Organisation | Recombinant vaccine |
US5032405A (en) * | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
US5616326A (en) * | 1990-01-25 | 1997-04-01 | The University Court Of The University Of Glasgow | Recombinant canine adenovirus 2 (CAV-2) |
FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US6165993A (en) * | 1992-03-23 | 2000-12-26 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US6511845B1 (en) | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
US6296852B1 (en) | 1993-04-14 | 2001-10-02 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
AU676042B2 (en) * | 1993-04-14 | 1997-02-27 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
EP0690912B1 (en) * | 1993-04-14 | 2008-03-05 | Commonwealth Scientific And Industrial Research Organisation | Recombinant avian adenovirus vector |
ES2196018T3 (es) * | 1993-08-11 | 2003-12-16 | Wyeth Corp | Vacunas de adenovirus recombinantes. |
GB2282601B (en) * | 1993-09-16 | 1998-04-15 | Solvay | Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same |
WO1998018453A1 (en) * | 1996-10-28 | 1998-05-07 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
ATE377087T1 (de) * | 1997-06-23 | 2007-11-15 | Univ Saskatchewan | Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors |
GB0222824D0 (en) * | 2002-10-02 | 2002-11-06 | Moredun Res Inst | Bacteriophage-mediated immunisation II |
DK1916995T4 (da) | 2005-07-29 | 2022-10-03 | Stichting Groningen Centre For Drug Res | Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf |
JP6454630B2 (ja) * | 2015-10-30 | 2019-01-16 | スティッチング フローニンゲン セントル フォー ドラッグ リサーチ | pH制御パルス送達システム、その調製法及び使用法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS535371A (en) * | 1976-07-02 | 1978-01-18 | Akebono Brake Ind Co Ltd | Braking circular plate |
EP0062574A3 (en) * | 1981-03-31 | 1982-12-29 | The Regents Of The University Of California | Virus protein synthesis |
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
-
1985
- 1985-10-18 IL IL76751A patent/IL76751A/xx not_active IP Right Cessation
- 1985-10-18 AU AU48840/85A patent/AU576907B2/en not_active Ceased
- 1985-10-21 CA CA000493420A patent/CA1263305A/en not_active Expired
- 1985-10-22 NZ NZ213920A patent/NZ213920A/en unknown
- 1985-10-22 IE IE261285A patent/IE58205B1/en not_active IP Right Cessation
- 1985-10-23 AT AT85307634T patent/ATE82509T1/de not_active IP Right Cessation
- 1985-10-23 EP EP85307634A patent/EP0181117B1/en not_active Expired - Lifetime
- 1985-10-23 GB GB08526156A patent/GB2166349B/en not_active Expired
- 1985-10-23 DE DE8585307634T patent/DE3586841T2/de not_active Expired - Fee Related
- 1985-10-24 PT PT81367A patent/PT81367B/pt unknown
- 1985-10-29 GR GR852592A patent/GR852592B/el unknown
- 1985-10-30 FI FI854257A patent/FI854257L/fi not_active Application Discontinuation
- 1985-10-30 DD DD28223185A patent/DD244357A5/de unknown
- 1985-10-31 NO NO854347A patent/NO854347L/no unknown
- 1985-10-31 PL PL25604985A patent/PL256049A1/xx unknown
- 1985-10-31 HU HU854173A patent/HU195619B/hu unknown
- 1985-10-31 DK DK501785A patent/DK501785A/da not_active Application Discontinuation
- 1985-10-31 JP JP60246103A patent/JP2609447B2/ja not_active Expired - Lifetime
- 1985-10-31 ES ES548397A patent/ES8900007A1/es not_active Expired
- 1985-10-31 KR KR1019850008092A patent/KR930012116B1/ko not_active IP Right Cessation
-
1987
- 1987-08-24 MY MYPI87001434A patent/MY101343A/en unknown
-
1991
- 1991-10-12 SG SG853/91A patent/SG85391G/en unknown
-
1992
- 1992-01-16 HK HK56/92A patent/HK5692A/xx not_active IP Right Cessation
- 1992-06-26 MX MX9203610A patent/MX9203610A/es unknown
-
1995
- 1995-09-13 JP JP7235069A patent/JP2614996B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DD244357A5 (de) | Verfahren zur Herstellung einer oralen Vakzine | |
DE69518910T4 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
DE69534902T2 (de) | Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen | |
US4920209A (en) | Oral vaccines | |
DE69126606T2 (de) | Vakzine | |
DE69425989T2 (de) | Neue Komplementations-Zelllinien für defekte adenovirale Vektoren | |
DE69636055T2 (de) | Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind | |
DE69534166T2 (de) | Rekombinanter adenovirus und methoden zu dessen verwendung | |
DE69635931T2 (de) | Komplementäre adenovirenvectorsysteme und zelllinien | |
DE69633565T2 (de) | Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie | |
DE60035124T2 (de) | Ein oncolytisches adenovirus | |
US5643579A (en) | Oral vaccines | |
DE60121471T2 (de) | Komplementierende zellinien | |
DE69834936T2 (de) | Vektor zur gewebespezifischen replikation und expression | |
DE69021002T2 (de) | Schimärische Hepadnavirus-Kernantigenproteine. | |
DE69837390T2 (de) | Rekombinanter schweine adenovirus vektor | |
DE69616559T2 (de) | Hilfsvirus für die herstellung von rekombinanten virusvektoren | |
EP1851239B1 (de) | Replikationsdefiziente rna-viren als impfstoffe | |
DE69914382T2 (de) | Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression | |
DE69828167T2 (de) | Rekombinante adenovirale vektoren, die eine spleissequenz enthalten | |
DE60017141T2 (de) | Replikationskompetente anti-krebs-vektoren | |
DE69333057T2 (de) | Rekombinente Adenoviren-Impfstoffe | |
EP0904394A1 (de) | Celo-virus | |
DE69535093T2 (de) | Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2 | |
DE69929530T2 (de) | Attenuierter pferdeherpesvirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF04 | In force in the year 2004 |
Expiry date: 20040325 |